Naxitamab is a humanized monoclonal antibody that binds to GD2 and helps the immune system kill cancer cells. Naxitamab has been approved in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.